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From Bench to Bedside
This approach can be used for cellular
therapies combined with tissue
engineering to provide delivery systems
for efficient use in the clinic. However, it
is first necessary to have an understanding
of the scope of new FDA and EU
regulations for cellular therapies, adequate
fundamental knowledge in order to make
the correct cell choice, and close
interdisciplinary collaboration to assure
the best developed delivery system and 
the manner in which this will be applied 
to the patient. Translational medicine is
the process where the interdisciplinary
biomedical community focuses on moving
research discoveries from the laboratory
into routine clinical practice in order to
diagnose and treat patients (see Figure 1).
CELL CHOICES, DELIVERY AND
REGULATION OF CELLULAR THERAPIES
Cellular therapy is becoming an interesting
addition to medical therapies for repairing,
restoring or ameliorating the function of
tissues. Some cell choices are more
adaptable to cellular therapy in patients.
Tissue choices from animals and humans at
all stages of development can be evaluated
with the advantages and disadvantages for
each final cell type (see Figure 2, page 32).
There is some confusion between the
terminology and potential of embryonic,
foetal and adult stem cells. This is
understandable since the terms are used 
for different contexts. In legal aspects, the
term ‘embryo’ denotes the earliest stages
following fertilisation of an ovum by a
sperm. A zygote would include early stage
cleavage embryos produced by cell division
up to 50- to 60-cell stage (each cell which
is a blastomere) and the blastocyte for the
60-cell stage to the point of implantation 
at about two weeks post-fertilisation.
Pathology would classify the embryonic
stage as up to nine weeks after gestation,
and thereafter until birth would be
classified as the foetal stage. 
From each of these tissues, different cell
lines can be established, but with a varying
Lee Ann Applegate at the University Hospital of Lausanne (CHUV/UNIL) and Dominique P Pioletti 
at the Swiss Federal Institute of Technology Lausanne (EPFL) investigate how translational 
medicine can bring safe cell therapies to the patient
Although we need to continue our efforts in basic sciences and research for the
discovery of fundamental knowledge, we also need to focus on how this knowledge
can improve human health. Often, it is not a single view or approach that will lead 
to discoveries, but rather the interface of disciplines that combine multiple fields 
of knowledge such as engineering, biology and medicine. An interdisciplinary
approach, allowing for a new way of thinking, can benefit the future of human 
health and enable new therapies to reach the clinic more rapidly. 
Figure 1: Translational medicine: interdisciplinary approach for cellular therapies
Multiple fields of expertise are necessary to develop a successful platform for translational medicine
of cellular therapies: lawyers for interpreting regulatory issues; biologists for the most appropriate cell
choice; engineers for delivery and tissue engineering design; and medical doctors for donor screening
and clinical application of final defined therapeutic cellular products. 
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range of complications in tissue culture
techniques. Embryonic stem cells are
developed from pre-implantation embryos
from the inner-cell mass before the first
two weeks of development. These cells are
frequently obtained from extra embryos
developed by in vitro fertilisation
techniques to aid couples for fertility
purposes. There has been a moratorium 
on the use of embryonic stem cells since
1975, with new laws in 1993 permitting
their use under certain circumstances.
These particular cells form the centre of
an ethical debate, and other researchers
have begun using foetal, embryonic cells
derived from voluntary interruption of
pregnancy between five and eight weeks.
Cell lines are normally developed from the
genital ridge of the foetus. As this tissue is
considered an organ donation in most
countries, it bypasses the major problems
that have been raised with regard to
embryonic stem cells. These cells are
indeed covered by federal funding which
was re-instated rather quietly by the Bush
administration in 2002. 
Most foetal cell research is developed from
specific tissues obtained at the latter end of
the first trimester (11 to 14 weeks) following
voluntary interruption of pregnancy, which is
considered legal in most countries. Cell lines
at this stage are tissue-specific and cells 
are therefore differentiated with specific
functions. Federal funding for these types of
cells was also affected by the moratorium
but re-instated in 2002, as the cells are
derived from a legal organ donation, as long
as the mother donor gives informed consent,
the tissue is a donation and not paid for, 
and that there is no change in timing or
method of pregnancy interruption for the
sake of research.
Since the 1930s, medical doctors and
scientists have used tissue from voluntary
pregnancy interruptions not only for
understanding cell biology but also as an
important entity in the development of
vaccines by using defined tissue-derived
cell lines. The Nobel Prize for Medicine 
in 1954 was awarded to American
immunologists who developed the polio
vaccine based on cultures of human 
foetal cells. Since this time, many other
necessary vaccines (rubella, chicken 
pox, hepatitis A and so on) have been
developed with the use of foetal cell lines
including two primary human diploid cell
lines which were originally prepared in the
1960s. The first cell line, WI-38 (Wistar
Institute 38) was developed by Leonard
Hayfleck in 1964 from foetal tissue from a
voluntary pregnancy interruption and later
given the ATCC (American Type Culture
Collection) number of CCL-75. This cell
line was used for the historical production
of vaccine RA 27/3 against rubella (1,2).
Adult stem cells, frequently referred to as
mesenchymal stem cells, have raised the
hopes of scientists for new treatments
because they have high self-renewal
capacity and can generate multiple cell
lineages. They can be isolated not only
from bone marrow but also from many
other tissues such as amniotic fluid,
adipose tissue, brain, skin, heart, kidneys
and liver. Although widely distributed,
adult stem cells represent only a small
fraction of a tissue cell population (often
only one for every 104 to 105 cells), 
which requires an extensive in vitro
expansion step. 
However, stem cell cultures are technically
very demanding. Maintenance and
expansion of stem cells in an
undifferentiated state require the addition
of many specific growth factors. Culture
of these cells without feeder layers (which
are usually formed by animal cells) is
difficult and feeder layers are responsible
for some aspects of inconsistent colony
cell growth. The need to use exogenous
growth factors as well as animal products
is a limiting factor for the scaling out 
of stem cell cultures for clinical
applications (3,4).
Unlike stem cells, foetal cells are
differentiated cells with high expansion,
regeneration and low immunogenic
properties. They can be isolated from
foetal tissues, which follow the embryonic
stage after nine weeks of development.
Foetal cells have extensive expansion
possibilities and cell culture requirements
are minimal compared to stem or
mesenchymal cell types. As the foetal cells
are already differentiated and do not need
to be directed or altered, the vast number
of additional growth factors normally
necessary are not needed for cell culture
and expansion (5-12).
Cell choice is of utmost importance and
each element of processing needs special
attention to produce a successful cell
therapy and to verify safety and
consistency before entering clinical trials.
Whole cell bioprocessing and adaptable
procedures to Good Manufacturing
Processes (GMP), which make it possible
to develop extensive master cell banks
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(MCB) and working cell banks (WCB),
will facilitate thorough testing (see Figure
3). Once MCBs are produced, WCBs 
can be created to establish individual
batches of treatments for high numbers of
patients. Further, these cell banks can be
thoroughly tested for safety with regard to
sterility, pathogens and adventitious agents
and tumorigenicity. Once safety is 
assured, efficient cell presentation with
biocompatible delivery systems can be
assessed for specific tissues. For delivery
systems, biocompatible biomaterials need
to be available in order to provide an
extracellular matrix environment for cell
differentiation, delivery and release. 
The cell and materials need to be 
tested together, not only to assure
biocompatibility, but also their
interactions, cellular stability and possible
degraded by-products of combination 
and degradation or absorption. Ease of
applicability of the final product will 
be of importance for clinical use.
All cellular products must be in
compliance with GMP guidelines 
with respect to medicinal products 
and investigational medicinal products 
for human use. The EU regulation on
advanced therapy medicinal products
(ATMP) was adopted in all European
Member States on 30th December 2008,
and the FDA recently also proposed
regulations on human cells, tissues and
cellular and tissue-based products. The
main scope of the regulations is to
establish clear classification criteria for
many new cell-based medicinal products.
For the EU, it makes reference to the
2004/23/EC directive on donation,
procurement and testing of human cells
and tissues, as well as the directive
2002/98/EC on human blood and blood
components. Together, these directives
dictate that human cells have to be in
compliance with the quality requirements
therein described, and that all ATMP have
to be prepared under GMP conditions.
Key elements, including identity, purity,
sterility, stability, safety and efficacy, 
are recommended for cellular-based
products. These new regulations impose 
a strict criteria for the production and
environment used for the production of
cell-based products for clinical trials and
treatments (13-15).
CLINICAL APPLICATION
Risk assessment of final cellular
products is of utmost concern. Self-
renewal of undifferentiated cells presents
a potential for tumour formation. Certain
techniques, such as cellular cloning or
encapsulation of cellular products, are
alternatives that can assure safety. Many
cellular-based therapies will not be
consistent regarding the total cell
population. Associated accessory cells
raise additional questions for potential
risk, as well as their physiological role
after administration. Cellular death of
transplanted cell populations, ectopic
tissue formation or migration from 
the site of administration could be
problematic when cellular therapies are
within anatomically sensitive areas, such
as for the central nervous system, joint
regions or myocardium. Preclinical
animal models for specific pathologies
or tissue repair are an important step,
and special care in the interpretation of
pertinent safety and biological activity
needs consideration. Appreciation of
relevant advantages and limitations 
needs to be well assessed for animal
model choice.
Figure 2: Cellular source and development stage
Cellular source can come from human and animals at different stages of development including
embryonic, embryonic-foetal, foetal and adult involving different beginning tissue sources ranging from
zygotes to specific tissues (bone marrow, adipose, amniotic fluid, skin, liver, bone, cartilage and so on)
Figure 3: Organisation of a cell therapy platform
Director of technical and logistics coordinates the programme with essential legal and ethical advisors
and a medical director for interpretation of medical quality assurance (serology and pathology reports).
The separation of hospitals for the organ donation and all other aspects of the platform including
serology, pathology and the GLP cell culture laboratory can assure complete anonymous and coded
organ donations. Importantly, the Director of Technical and Logistics is not involved in any manner in
the organ donation process as required by law. Final approval for use of validated cell banks for
human therapy is coordinated and approved with both Hospital Ethics Committees and national
regulatory agencies (such as EMEA, FDA and SwissMedic).
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CONCLUSION
Cell-based therapies are being developed
and introduced for all types of tissue
repair including skin, bone, cartilage,
muscle and spine, among others (5-12,
16). They offer promise for repairing and
replacing damaged tissue and restoring
lost functionality. One of the major
challenges for assuring that more patients
will benefit from cell-based therapies 
in the future will be the optimisation of
the choice of cell type, as well as their
isolation and proliferation. Equally
important will be the delivery system of
the cell choice and their interaction with
these scaffolds to assure biocompatibility.
The development of MCB from the cell
choice provides a major advantage for the
creation of a therapeutic biological agent.
Careful selection of donors and extensive
screening of both the donor and cultured
cells avoids transmissible viral, fungal 
or bacterial disease and therefore can
provide a safe and secure use of cells for
therapeutic purposes. Clear regulatory
affairs of cellular use, particularly for
organ donation of embryonic and foetal
cells, will be necessary to help researchers
and clinicians in future therapies (17-19).
Overall, cooperative interdisciplinary
efforts and cooperation to form successful
translational medicine platforms in
universities and hospitals will help to
ensure further patient safety.
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